Copenhagen-based EvodiaBio, which produces natural flavors through yeast-based fermentation, has secured €6 million (DKK 45 million) in funding to expand in current markets and enter the Asian market.
- Founded in 2021 by Jarne Elleholm and Sotirios Kampranis, EvodiaBio develops natural flavors using precision fermentation. The company produces monoterpenes, volatile aroma molecules found in hops and other plants, at commercial scale by engineering yeast to replicate the plant pathways that generate these compounds.
- Their platform, Yops®, allows controlled, industrial-scale production of specific natural aromas, which can be incorporated into beverages, food, and other products. This process reduces reliance on harvested plants and lowers environmental impact while providing consistent and customizable flavor profiles.
Details of the deal
- The funding round was led by US-based RA Capital Management’s Planetary Health Fund and included new investors Wild Radicals and Francis Family Funds, along with existing investors EIFO, Ananke Ventures, Newtree Impact, PINC (Paulig), the company’s co-founders Jarne Elleholm and Sotirios Kampranis, CEO Camilla Kloss Fenneberg, and board members Flemming Besenbacher, Anne Cabotin, and Andreas Fibig.
- EvodiaBio will use the €6 million funding to expand into new markets, particularly in Asia, scale its fermentation-based aroma technology across beverages and other industries, strengthen strategic partnerships, and accelerate global growth with its Yops platform.
"This investment puts us in a position to scale globally. I am proud of our team – within just three and a half years, we have gone from a research project to industrial production with all necessary approvals and a profitable product. That is rarely seen in the biotech industry. This investment enables us to accelerate global growth and realize our ambition of becoming a Danish unicorn in industrial biotech," claims Camilla Kloss Fenneberg, CEO of EvodiaBio.
